Ascendis Pharma A/S
| |
Ascendis Pharma A/S | |
---|---|
Type | Public |
Industry | BioTechnology |
Founded | 2007 |
Headquarters | Capital Region of Denmark, Denmark |
Key people | 55 [1] |
Investors | Gilde Healthcare Partners, OrbiMed, RA Capital Management, Rock Springs Capital, Sofinnova Partners, Sofinnova Ventures, TechnoStart, Venrock, Vivo Capital [2] |
Number of employees | Jan Møller Mikkelsen (Co-Founder, President and CEO), Martin Auster (CBO), Michael Beckert (Chief Medical Officer (acting)), Thomas Soloway (CFO) |
Ascendis Pharma A/S is an emerging pharmaceutical company which is creating improved, patentable versions of both currently marketed drugs and high-value development-stage opportunities. The company is built upon a novel transient linker technology, TransientLink, which conjugates peptides, proteins and small molecules to a carrier molecule in a reversible fashion. This unique reversibility allows an unmodified active drug to be released (unlinked) in the body in a precise, time-controlled fashion, creating a long-acting effect. Conventional conjugation technologies are unable to achieve this type of slow-release mechanism because the polymer cannot de-link from the drug. [3]
Contents
Products
Ascendis Pharma A/S, a clinical stage biopharmaceutical company
- It develops various prodrug therapies to treat unmet medical needs.
- It is developing TransCon human growth hormone that has completed Phase II clinical trials in children and adults to treat growth hormone deficiency (GHD) and other indications
- TransCon Treprostinil that has completed Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries.
- The company is also developing TransCon Peptides for the treatment of diabetes
- TransCon Ranibizumab, a compound to support injection of ranibizumab.
- It has strategic collaborations with Sanofi and Genentech
Controversies
None Reported
Top 5 Recent Tweets
Date | Author | Comment |
---|---|---|
February 02, 2023 | quantisnow | $ASND 📜 SEC Form SC 13G filed by Ascendis Pharma A/S 45 seconds delayed. |
January 31, 2023 | HedgeFundRisk | What Makes Ascendis Pharma A/S (ASND) an Attractive Investment Choice? - Yahoo Finance https://t.co/Cao6ia4Rxl https://t.co/K5Ap218mQ8 |
January 29, 2023 | Tian_A1 | #Barclays PLC owns 12.89 million of Ascendis Pharma A/S #Stock [ https://t.co/8HOZKSJStf ] Following the completion… https://t.co/OLdAFSIeDU |